The Many Microenvironments of Ovarian Cancer
Open accessThe DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
High-grade serous ovarian cancer (HGSOC) is the most common and deadly subtype of ovarian cancer as it is commonly diagnosed after substantial metastasis has already occurred. The past two decades have been an active era in HGSOC research, with new information on the origin and genomic signature of the tumor cell. Additionally, studies have begun to characterize changes in the HGSOC microenvironment and examine the impact of these changes on tumor progression and response to therapies. While this knowledge may provide valuable insight into better prognosis and treatments for HGSOCs, its collection, synthesis, and application are complicated by the number of unique microenvironments in the disease-the initiating site (fallopian tube), first metastasis (ovary), distal metastases (peritoneum), and recurrent/platinum-resistant setting. Here, we review the state of our understanding of these diverse sites and highlight remaining questions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current research suggests that HGSOC initiates in the fallopian tube, then metastasize to the ovaries and can then spread to secondary metastatic sites via lymphatic, hematogenous and transcoelomic routes, whereby the latter is the most frequent (Micek et al., 2020).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Micek et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Secondary metastatic sites can include the mesentery, the liver, the omentum or the peritoneum (Micek et al., 2020).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Micek et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366 · cited 1×
“CAFs produce ECM molecules, including collagen I and fibronectin, and ECM remodeling enzymes, including MMPs, dynamically changing the structure and mechanics of the microenvironment in many solid cancers (Kalluri 2016).”
BackgroundAdipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2492 · Cited by 2,279
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
Wyckoff, J., Wang, W., Lin, E. Y., Wang, Y., Pixley, F., Stanley, E. R., Graf, T., Pollard, J. W., Segall, J., & Condeelis, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1449 · Cited by 1,188
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology*
Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K., & Leung, P. C. K. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0422 · Cited by 1,046
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 898
Cited by
Mo, Y., Leung, L. L., Mak, C. S. L., Wang, X., Chan, W.-S., Hui, L. M. N., Tang, H. W., Siu, M. K. Y., Sharma, R., Xu, D., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01703-9 · Cited by 107
Targeted drug conjugate systems for ovarian cancer chemotherapy
Ogundipe, O. D., Olajubutu, O., & Adesina, S. K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115151 · Cited by 48
The emerging role of glycolysis and immune evasion in ovarian cancer
Jin, B., Miao, Z., Pan, J., Zhang, Z., Yang, Y., Zhou, Y., Jin, Y., Niu, Z., & Xu, Q. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03698-x · Cited by 26
“A study showed that numerous cytokines in follicular fluid such as insulin-like growth factors (IGF), epidermal growth factor (EGF) and transforming growth factor-β (TGF-β) induce tumor cell proliferation and invasion [9].”
Micek, H. M., Yang, N., Dutta, M., Rosenstock, L., Ma, Y., Hielsberg, C., McCord, M., Notbohm, J., McGregor, S. M., & Kreeger, P. K. (2024) · Science Advances · doi:10.1126/sciadv.adl4463 · Cited by 26
Self-citationMicrophysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Metadata
- Authors
- Micek, H. M., Visetsouk, M. R., Fleszar, A. J., & Kreeger, P. K.
- Affiliations
- University of Wisconsin–Madison (US)
- Corresponding author
- Kreeger, Pamela K.
- Venue
- Advances in experimental medicine and biology
- Publisher
- Springer International Publishing
- Published
- 2020
- Volume
- 1296
- Pages
- 199-213
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- PMC
- PMC8687602
- OpenAlex
- W3174202789
- Cited by
- 14
- References
- 108
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 2 · 2023: 4 · 2022: 1
- FWCI
- 8.17
- Type
- book chapter
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA232517, R21CA227922, R01CA240965)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- high-grade serous ovarian cancer, tumor microenvironment, fallopian tube origin, peritoneal carcinomatosis, platinum resistance, recurrent ovarian cancer, tumor progression, treatment response, prognosis
- MeSH terms
- Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Fallopian Tubes, Female, Humans, Ovarian Neoplasms, Cystadenocarcinoma, Serous, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Many Microenvironments of Ovarian Cancer. https://app.cochat.ai/papers/10.1007/978-3-030-59038-3_12
- The paper
- Micek, H. M., Visetsouk, M. R., Fleszar, A. J., & Kreeger, P. K. (2020). The Many Microenvironments of Ovarian Cancer. Advances in experimental medicine and biology. https://doi.org/10.1007/978-3-030-59038-3_12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.